Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model
Metrics: PDF 1237 views | HTML 1984 views | ?
Florian C. Maier1, Julia Schmitt1, Andreas Maurer1, Walter Ehrlichmann1, Gerald Reischl1, Konstantin Nikolaou2, Rupert Handgretinger3, Bernd J. Pichler1, Wolfgang M. Thaiss1,2
1Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany
2Department of Radiology, Eberhard Karls University Tübingen, Tübingen, Germany
3University Childrens Hospital, Eberhard Karls University Tübingen, Tübingen, Germany
Wolfgang M. Thaiss, email: [email protected]
Keywords: Cerenkov luminescence imaging, positron emission tomography, neuroendocrine tumor, mouse imaging, monoclonal antibody
Received: February 22, 2016 Accepted: August 24, 2016 Published: September 01, 2016
Antibody-based therapies gain momentum in clinical therapy, thus the need for accurate imaging modalities with respect to target identification and therapy monitoring are of increasing relevance. Cerenkov luminescence imaging (CLI) are a novel method detecting charged particles emitted during radioactive decay with optical imaging. Here, we compare Position Emission Tomography (PET) with CLI in a multimodal imaging study aiming at the fast and efficient screening of monoclonal antibodies (mAb) designated for targeting of the neuroblastoma-characteristic epitope disialoganglioside GD2. Neuroblastoma-bearing SHO mice were injected with a 64Cu-labeled GD2-specific mAb. The tumor uptake was imaged 3 h, 24 h and 48 h after tracer injection with both, PET and CLI, and was compared to the accumulation in GD2-negative control tumors (human embryonic kidney, HEK-293). In addition to an in vivo PET/CLI-correlation over time, we also demonstrate linear correlations of CLI- and γ-counter-based biodistribution analysis. CLI with its comparably short acquisition time can thus be used as an attractive one-stop-shop modality for the longitudinal monitoring of antibody-based tumor targeting and ex vivo biodistribution.
These findings suggest CLI as a reliable alternative for PET and biodistribution studies with respect to fast and high-throughput screenings in subcutaneous tumors traced with radiolabeled antibodies. However, in contrast to PET, CLI is not limited to positron-emitting isotopes and can therefore also be used for the visualization of mAb labeled with therapeutic isotopes like electron emitters.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.